Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Milestone Pharmaceuticals ( (MIST) ) has provided an announcement.
Milestone Pharmaceuticals reported fourth-quarter and full-year 2025 results alongside the U.S. launch progress of its newly approved PSVT therapy, CARDAMYST nasal spray. The FDA approval in December 2025 delivers the first new PSVT treatment option in three decades, enabling more than two million U.S. patients to self-administer a rapid-acting therapy outside emergency settings.
Commercial rollout is advancing with a 60-person national sales force, broad retail pharmacy availability, and early prescription data indicating meaningful initial demand among targeted cardiology prescribers. The company has roughly $200 million in pro forma cash to fund the launch and operations into late 2027, is pursuing European approval under the TACHYMIST brand by the first half of 2027, and is planning a Phase 3 program in atrial fibrillation with rapid ventricular rate to expand etripamil’s clinical and commercial footprint.
The most recent analyst rating on (MIST) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.
The score is held down primarily by weak financial performance (large losses, substantial cash burn, and higher leverage) and a technically weaker longer-term trend (below 50/100/200-day averages with slightly negative MACD). Positive corporate events (U.S. launch, non-dilutive financing, and EU regulatory progress) provide meaningful upside catalysts but do not yet offset the current financial risk profile.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines. Its lead product is CARDAMYST (etripamil) nasal spray, targeting acute symptomatic paroxysmal supraventricular tachycardia (PSVT), with an additional market focus on potential uses in atrial fibrillation with rapid ventricular rate.
Average Trading Volume: 2,417,007
Technical Sentiment Signal: Strong Sell
Current Market Cap: $144.8M
See more insights into MIST stock on TipRanks’ Stock Analysis page.